Latest Content

A study at IKCS finds higher BMI after kidney cancer diagnosis improves survival, while significant weight loss predicts poorer outcomes.

American Indian and Alaskan Native individuals face some of the highest kidney cancer burdens in the United States.

I want to appreciate and acknowledge the one person who has had a profoundly positive impact on me throughout my 16-year journey with chronic small lymphocytic lymphoma.

In honor of Lung Cancer Awareness Month, CURE spoke with Dr. Daniel J. Boffa about how the understanding of lung cancer is evolving beyond smoking.

FOG-001 received fast track designation after early study results showed tumor shrinkage in all evaluable patients with desmoid tumors.

Following the 2025 ESMO Congress, Dr. Joshua Saba sat down with Dr. Chandler Park to discuss recent advances in prostate cancer care.

A woman shares how vision loss led to her cancer diagnosis and how lifestyle changes, support and community helped her regain control after her cancer had spread.

Cindy and Katie share how caring for parents with cholangiocarcinoma led to friendship, support and advocacy through the Cholangiocarcinoma Foundation.

The FDA approved Poherdy as the first interchangeable biosimilar to Perjeta for patients with HER2-positive breast cancer.

The FDA has granted orphan drug designation to tinostamustine, an investigational therapeutic, for the treatment of patients with malignant gliomas.

The FDA approved Komzifti in relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.

Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data presented at the 2025 ESMO Congress.

Leading oncology experts share emerging research and developments shaping the year ahead, from precision medicine to innovative cancer therapies.